Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. reports developments in remote patient monitoring, cardiac diagnostics and chronic condition management. The company operates a Technology-as-a-Service model built around remote cardiac monitoring solutions for medical and consumer markets, including Bioheart wearable monitoring and cloud-based workflow tools.
Recurring news covers financial results, revenue trends, margin performance, operating efficiency and business update calls. Company updates also include adoption of remote cardiac monitoring solutions, collaborations for consumer wearable ECG data, and the use of automation and AI-enabled cloud infrastructure in cardiac monitoring workflows.
Biotricity, Inc. (OTCQB:BTCY) has initiated its strategy to uplist to a major exchange in 2021, highlighting its commitment to enhance shareholder value. The company has submitted an application for listing, aiming to align its capital needs with growth potential in a market exceeding $3 billion in annual sales. CEO Waqaas Al-Siddiq reaffirmed the company's plans to broaden its investor base and capitalize on market opportunities as they progress towards uplisting.
Biotricity (OTCQB:BTCY) will present its flagship product, Bioflux, at the Benzinga Global Small Cap Conference on May 14, 2021. The presentation, led by CEO Waqaas Al-Siddiq, will focus on Bioflux, a wearable device for real-time cardiac monitoring and diagnosis. Scheduled for 3:35 PM ET, investors can register for access and view the presentation on YouTube. Biotricity is redefining remote healthcare with innovative monitoring solutions aimed at chronic conditions. For more information, visit biotricity.com.
Biotricity (OTCQB:BTCY) announced that its Biotres device is a finalist in Fast Company's 2021 World Changing Ideas Awards. This recognition reflects the company's commitment to innovation in healthcare technology. Dr. Waqaas Al-Siddiq, CEO, emphasized the device's potential to enhance cardiac diagnostics by providing timely patient insights for better detection and diagnosis of heart conditions. The awards program selected 400 finalists from over 4,000 entries, underscoring Biotricity’s innovative efforts in improving healthcare quality and patient compliance.
Biotricity Reports Record Revenue Growth
Biotricity (OTCQB:BTCY) announces a remarkable 133% increase in gross revenues for fiscal 2021, totaling $3.3 million. The fourth quarter alone saw a 203% year-over-year revenue boost. March 2021 set a record with over $580,000 in technology fees, projecting a revenue run rate of approximately $7 million annually. The company remains optimistic about continued growth, driven by reopening businesses post-COVID and a solid recurring revenue model.
Biotricity Inc. (OTCQB: BTCY) announced a new interview featuring CEO Dr. Waqaas Al-Siddiq, discussing the company's innovative cardiac monitoring solutions. The flagship product, Bioflux®, is a wearable device enabling real-time cardiac patient monitoring. Biotricity's growth strategy includes expanding its sales presence across 20 U.S. states, building a sales force, and launching new products. Dr. Al-Siddiq emphasizes the company’s focus on technology over clinical practices, reinforcing a recurring revenue model aimed at enhancing long-term value for investors.
Biotricity (OTCQB:BTCY) announced that CEO Waqaas Al-Siddiq will present at Maxim Group's Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. Al-Siddiq will participate in a Healthcare IT panel on March 18 from 3:30-4:30 PM ET and a fireside chat on March 19 from 11:30 AM-12:00 PM ET. Investors can register for the conference and request one-on-one meetings with Biotricity management post-conference. Biotricity focuses on innovative remote health monitoring solutions for chronic care management.
Biotricity (OTCQB:BTCY) announced its unaudited financial results for Q3 fiscal 2021, reporting a record revenue of $1 million, reflecting a remarkable 162% year-over-year increase and a 34.5% sequential growth. The gross margin improved to 49.2% from 43.6% in the prior quarter. Despite a net loss of $0.11 per share, the company anticipates continued triple-digit revenue growth for the remainder of 2021, supported by resources from convertible debt financing and a planned geographic expansion. Full results will be available on EDGAR on February 16, 2021.
Biotricity, Inc. (OTCQB:BTCY) announced a call on February 11, 2021, to discuss its third-quarter financial results for fiscal 2021, covering the period ending December 31, 2020. Full results will be available on February 16, 2021. The call will take place at 1:30 PM PT and will include a live webcast for analysts and investors. Interested parties can join by dialing 323-289-6581 or 866-248-8441, using passcode 9555546. Biotricity focuses on remote health monitoring solutions and aims to improve chronic care management through innovative diagnostic technologies.